Literature DB >> 2944965

Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors.

N K Damle, L V Doyle, E C Bradley.   

Abstract

When cultured with native or recombinant human interleukin 2 (IL 2), human peripheral blood non-adherent mononuclear cells (NAMNC) acquire the ability to lyse both NK-sensitive and NK-resistant tumor target cells. The development of these IL 2-activated killer (IAK) cells, also known as LAK, is observed in the absence of exogenous antigen or mitogen. This study describes the ability of various subpopulations of human peripheral blood NAMNC with defined surface phenotype to generate the IAK activity. Human NAMNC were separated into various subpopulations on the basis of the ability to bind monoclonal antibodies, activated with IL 2, and were examined for the cytolytic effect on various tumor target cells. Although CD16+ (Leu-11+) NK cells from NAMNC could become IAK cells when cultured with IL 2, removal of these cells from NAMNC had no effect on the latter's ability to generate the IAK effect. When CD16- NAMNC were separated into CD2+ E rosette-forming T cells (ERFC) and CD2- non-T (non-ERFC) subpopulations, both subpopulations generated the IAK activity. The ability of monoclonal antibody-defined subpopulations of T and non-T cells to generate IAK cells was then examined. Both CD4+ and CD8+ subsets isolated by either positive or negative selection generated the IAK activity. Similarly, CD20+ (B1+) B cells and CD20- non-T (null) cells developed into IAK cells when cultured with IL 2. In contrast, Leu-7+ T cells failed to generate the IAK activity. CD4+ and CD8+ subsets were additionally separated into narrower subpopulations by using monoclonal antibodies anti-Leu-8 and 9.3 respectively, and were examined for their ability to generate IAK cells. Precursors of IAK cells were derived from each of the four: CD4+, Leu-8+ (inducer), CD4+, Leu-8- (helper/amplifier), CD8+, 9.3+ (cytolytic), and CD8+, 9.3- (suppressor) subpopulations of T cells. Thus, the IAK activity appears to be derived from phenotypically heterogeneous and otherwise functionally diverse human lymphoid cells and is not confined to any single subpopulation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2944965

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

Review 1.  Cancer therapy with bispecific antibodies: Clinical experience.

Authors:  Archana Thakur; Lawrence G Lum
Journal:  Curr Opin Mol Ther       Date:  2010-06

2.  Defective interleukin-2 induction of lymphokine-activated killer (LAK) activity in peripheral blood T lymphocytes of patients with monoclonal gammopathies.

Authors:  M Massaia; A Bianchi; U Dianzani; A Camponi; C Attisano; M Boccadoro; A Pileri
Journal:  Clin Exp Immunol       Date:  1990-01       Impact factor: 4.330

3.  Combination chemo-immunotherapy: kinetics of in vivo and in vitro generation of natural killer cells and lymphokine-activated killer cells in the rat.

Authors:  L S Stewart; H F Sewell; A W Thomson
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

4.  TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity.

Authors:  E A Grimm; W L Crump; A Durett; J P Hester; S Lagoo-Deenadalayan; L B Owen-Schaub
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

5.  Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma.

Authors:  P M Anderson; F H Bach; A C Ochoa
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

6.  Differential effects of BCNU on T cell, macrophage, natural killer and lymphokine-activated killer cell activities in mice bearing a syngeneic tumor.

Authors:  M Nagarkatti; P S Nagarkatti; A M Kaplan
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

7.  Induction of lymphokine-activated killer cells from rat thymocytes using recombinant human interleukin-2.

Authors:  H Imaya; H Matsuura; M Kudo; S Nakazawa
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

8.  Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity.

Authors:  B Brooks; R C Rees
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

9.  Release of cytokines during generation of lymphokine-activated killer (LAK) cells by IL-2.

Authors:  G A Limb; A Meager; J Woolley; M Wadhwa; J Biggerstaff; K A Brown; R A Wolstencroft
Journal:  Immunology       Date:  1989-12       Impact factor: 7.397

Review 10.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.